Clinical Trials Logo

Filter by:
NCT ID: NCT04727008 Recruiting - Multiple Myeloma Clinical Trials

CXCR4 Modified Anti-BCMA CAR T Cells for Multiple Myeloma

Start date: September 21, 2022
Phase: Phase 1
Study type: Interventional

Multiple myeloma (MM) is an incurable plasma cell cancer that almost all patients eventually relapse despite advancement in treatment strategies. B-cell maturation antigen (BCMA) is a cell surface receptor that expressed primarily by malignant and normal plasma cells. This study aims to evaluate the safety and tolerance CXCR4 modified BCMA CAR T cells in treating standard treatment failed refractory/relapsed multiple myeloma, and will follow dose-escalating cohorts. The efficacy of CXCR4 modified BCMA CAR T will also be investigated.

NCT ID: NCT04726956 Recruiting - Clinical trials for Pancreatic Ductal Adenocarcinoma

A Combination of AKR1B10 and CA19-9 Improves the Diagnosis of PDAC

Start date: February 1, 2021
Phase:
Study type: Observational

The purpose of this study is to clarify the diagnostic significance of AKR1B10 in patients with pancreatic ductal adenocarcinoma, and to combine with CA19-9 to improve the diagnosis rate of pancreatic ductal adenocarcinoma.

NCT ID: NCT04726501 Recruiting - Hodgkin Lymphoma Clinical Trials

CCCG-HD-2018 for Children and Adolescents With Newly Diagnosed Hodgkin Lymphoma

Start date: April 1, 2018
Phase: Phase 4
Study type: Interventional

The incidence of Hodgkin's lymphoma (HL) in Chinese children and adolescents is only 1 / 10 of that in Europe and the United States, which is a "rare" childhood tumor. Due to the "drug shortage" and extremely low incidence, it has brought great difficulties to the domestic clinical research and failed to achieve the desired effect. In this study, we apply a well-documented effective protocol on newly diagnosed children and adolescents with HL to understand whether the same treatment regimens can obtain similar event free survival rates and overall survival rates and then find out the problems existing in the current clinical care of HL in China, so as to make continuous improvement in the future and prepare for innovative clinical research.

NCT ID: NCT04725994 Recruiting - Gastric Cancer Clinical Trials

Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer

Start date: June 28, 2021
Phase: Phase 1
Study type: Interventional

This is an open-label, Phase 1b study to evaluate the safety and tolerability of IDX-1197 and determine the MTD and RP2D in combination with XELOX or irinotecan in patients with advanced gastric cancer.

NCT ID: NCT04725448 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma

Start date: April 6, 2021
Phase: Phase 2
Study type: Interventional

This study aimed to evaluate the efficacy and safety of first-line Toripalimab combined with bevacizumab, nab-paclitaxel and carboplatin in the treatment of patients with advanced pulmonary sarcomatoid carcinoma.

NCT ID: NCT04725227 Recruiting - ARDS Clinical Trials

Determine the Effect of Prone Positioning in Adults With ARDS by Electrical Impedance Tomography

Start date: December 1, 2020
Phase:
Study type: Observational

determine the effect of prone positioning on ventilation and perfusion distribution in adults with acute respiratory distress syndrome by electrical impedance tomography

NCT ID: NCT04725214 Recruiting - Clinical trials for MGMT-Unmethylated Glioblastoma

Anlotinib Combined With STUPP for MGMT Nonmethylated Glioblastoma

Start date: January 15, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test the efficacy and safety of Anlotinib in combination with STUPP regimen for MGMT promoter nonmethylated glioblastoma.

NCT ID: NCT04725032 Recruiting - Brain Tumor Adult Clinical Trials

Effects of Intravenous Anesthesia and Balanced Anesthesia on Flash Visual Evoked Potentials

Start date: January 25, 2021
Phase: N/A
Study type: Interventional

Intraoperative flash visual evoked potentials (FVEPs) could monitor visual function during neurosurgery. There are fewer reports comparing the effects of sevoflurane-propofol balanced anesthesia and propofol-based total intravenous anesthesia under comparable bispectral index (BIS) levels on the amplitude and latency of flash visual evoked potentials (FVEPs) for sellar or parasellar tumors resection neurosurgeries.

NCT ID: NCT04724876 Recruiting - Clinical trials for Central Nervous System Infections and Inflammations

Meningitis Encephalitis: a Metagenomics-Based Etiology & Epidemiology Research

MEMBER
Start date: December 31, 2020
Phase:
Study type: Observational [Patient Registry]

Autoimmune encephalitis (AE) is caused by abnormal immune response mediated by autoimmune antibodies of patients, which can be detected by a serial of autoimmune antibodies[4,5,6,7]. At present, the traditional infection diagnosis mainly relies on microbial culture method, which has the characteristics of long cycle, high cost, low detection rate and complex detection process. About 30-60% of encephalitis have unknown etiology[2,3]. On the other hand, the diagnosis and classification of noninfectious encephalitis mainly depend on the detection of autoimmune antibodies, the scope of diagnosis and differential diagnosis is limited, and the relationship between autoimmune encephalitis and infection factors is still unclear. Metagenomics sequencing (mNGS) is a new method that does not rely on microbial culture and can directly detect pathogenic nucleic acids. It has the characteristics of fast, accurate, high throughput, no preference for different pathogen detection, and can detect known and unknown pathogens at the same time. Nowadays, mNGS is widely used in the field of pathogen detection.

NCT ID: NCT04724798 Recruiting - Pharmacokinetics Clinical Trials

Population Pharmacokinetics of Tigecycline in Patients Treated With ECMO

Start date: January 20, 2020
Phase:
Study type: Observational

Tigecycline is a commonly used antibiotic in critically ill patients. The pharmacokinetics (PK) of tigecycline in intensive care unit (ICU) patients can be affected by severe pathophysiological changes so that standard dosing might not be adequate. At present, a number of studies have reported that ECMO will affect the PK of anti-infective drugs and lead to treatment failure. The purpose of this study was to describe the population PK of tigecycline in patients treated with ECMO and to evaluate the relationship between individual PK parameters and patient covariates.